FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

High Court Pauses Limits on Mifepristone

The U.S. Supreme Court issues a temporary pause on a 5/1 lower court ruling that would have curtailed access to the abortion pill mifepristone.

latest-news-card-1
Biologics

Scrutiny of Gene Therapy Evidence Intensifies After Recent Setbacks

An opinion article notes that recent FDA regulatory decisions are leading to a sharper focus on the evidentiary standards underpinning cell and gene t...

latest-news-card-1
Federal Register

Alnylam Pharmas Web Promo is Misleading: FDA

FDA sends an untitled letter to Alnylam Pharmaceuticals, citing misleading promotional claims on a consumer-facing Web site for its drug Amvuttra.

latest-news-card-1
Human Drugs

Bayer DTC Materials Run Afoul of FDA

FDA issues an untitled letter to Bayer HealthCare Pharmaceuticals, citing misleading direct-to-consumer advertising for its prostate cancer drug Nubeq...

latest-news-card-1
Human Drugs

Makary Outlines Sweeping Reforms to Speed Drug Development

FDA commissioner Marty Makary outlines his goals to overhaul how the agency reviews new drugs, aiming to reduce early-stage regulatory friction, accel...

latest-news-card-1
FDA General

Turmoil, Turnover and Industry Backlash Mark Makarys Tenure

New Bloomberg reporting that FDA is facing mounting internal strain and external criticism just over a year into commissioner Marty Makarys tenure.

latest-news-card-1
Human Drugs

Clene Plans ALS Drug Filing After Input on Accelerated Path

Clene says it plans to submit an NDA in the third quarter for its experimental amyotrophic lateral sclerosis therapy.

latest-news-card-1
Human Drugs

Allergans Ireland Plant Hit With 483 After Inspection

FDA cites multiple manufacturing and quality control deficiencies at a facility operated by Allergan Pharmaceuticals in Ireland following an inspectio...

Biologics

Town Hall on BLA Submissions for Cell and Gene Therapies

FDA plans a 6/4 town hall meeting aimed at guiding drug developers through the process of preparing BLAs for cell and gene therapy products. The CBER ...

latest-news-card-1
Federal Register

PhRMA Urges Changes to FDAs Plausible Mechanism Guidance

PhRMA urges FDA to broaden and clarify its draft guidance on individualized therapies, warning that overly narrow definitions and unclear expectations...